Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Bosch-Vizcaya A
- Pérez-García A
- Brunet S
- Solano C
- Buño I
- Guillem V
- Martínez-Laperche C
- Barrenetxea C
- Martínez C
- Tuset E
- Lloveras N
- Coll R
- Guardia R
- González Y
- Roncero JM
- Bustins A
- Gardella S
- Fernández C
- Buch J
- Gallardo D
- GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (
Abstract
CTLA-4 (cytotoxic T-lymphocyte antigen-4) plays a pivotal role in inhibiting T cell activation through competitive interaction with B7 molecules and interruption of costimulatory signals mediated by CD28. Polymorphisms on the CTLA-4 gene have been previously associated with autoimmune diseases, predisposition to leukemic relapse, and with graft-versus-host disease (GVHD) or relapse after allogeneic transplant. As CTLA-4 is expressed on T-lymphocytes, the aim of this study was to determine whether the donor CTLA-4 CT60 genotype also influences clinical outcome even after T cell depletion with CD34-positive selection. We studied 136 patient-donor pairs. Overall survival (OS) was worse for those patients who received grafts from a donor with the CT60 AA genotype rather than from a donor with the AG or GG genotype (35.6% vs 49.4%; P = .043). This association was confirmed through multivariate analysis, which identified the donor CT60 genotype as an independent risk factor for OS (P = .008; hazard ratio [HR]: 2.24, 95% confidence interval [CI]: 1.23-4.08). The donor CT60 AA genotype was also associated with lower disease-free survival, this being related to an increased risk of relapse (P = .001; HR: 3.41, 95% CI: 1.67-6.96) and a trend toward higher transplant-related mortality. These associations were stronger when considering only patients in the early stage of disease. Our results suggest that graft-versus-leukemia (GVL) activity after T cell depletion is conditioned by the donor CTLA-4 genotype.
Datos de la publicación
- ISSN/ISSNe:
- 1083-8791, 1523-6536
- Tipo:
- Article
- Páginas:
- 100-105
- PubMed:
- 21703972
- Factor de Impacto:
- 2,104 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 15
Documentos
- No hay documentos
Filiaciones
Cita
Bosch A,Pérez A,Brunet S,Solano C,Buño I,Guillem V,Martínez C,SANZ G,Barrenetxea C,Martínez C,Tuset E,Lloveras N,Coll R,Guardia R,González Y,Roncero JM,Bustins A,Gardella S,Fernández C,Buch J,Gallardo D,GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (. Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors. Biol. Blood Marrow Transplant. 2012. 18. (1):p. 100-105. IF:3,940. (1).
Portal de investigación